Home › Colorectal Cancer › NCT05234177
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
RecruitingObservational study
Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Known or suspected colorectal adenocarcinoma (Stage I to IVA disease) * Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent. * 18 years old or older * Willing and able to provide informed consent * Willing to have additional blood samples collected during routine surveillance visits Exclusion Criteria: * Not willing to have additional blood samples collected * Pathology that is not consistent with colorectal adenocarcinoma
About the study
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
What is being tested
- Observation (other)
Sponsor: Tempus AI · Participants: 300 · Started: Jun 21, 2022
Contact the study team
- CRC Surveillance Study · Phone: (833) 514-4187
Official record on ClinicalTrials.gov — NCT05234177
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.